Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ChiCTR2400082391Phase 2Recruiting
Phase 2, open-label, single-arm trial of fruquintinib in colorectal cancer (CRC), sponsored by Suining Central Hospital. Primary endpoint: Objective response rate. Started Mar 2024; status: recruiting.
Beyond the preview
Study design, results and competitive context are available in the Gosset platform where reported.
Available in the Gosset platform where reported.
Available in the Gosset platform where reported.
See how Gosset can support your research on ChiCTR2400082391.